Aerie Pharmaceuticals

Drug Name	Phase	Indication	Designations	Patent
Netarsudil ophthalmic solution 0.02%	Phase 3	Primary Open Angle Glaucoma	-	-
PG324 Ophthalmic Solution 0.02%/0.005%	Phase 3	Open-angle Glaucoma	-	-
Timolol maleate Ophthalmic Solution 0.5% BID	Phase 3	Ocular Hypertension	-	-
0.003% AR-15512 ophthalmic solution	Phase 3	Dry Eye Disease	-	-
AR-15512 vehicle ophthalmic solution	Phase 3	Dry Eye Disease	-	-
AR-13324 Ophthalmic Solution 0.02%	Phase 3	Ocular Hypertension	-	-
Netarsudil (AR-13324) ophthalmic solution 0.02%	Phase 3	Open-angle Glaucoma	-	-
AR-13324 Ophthalmic Solution 0.02% BID	Phase 3	Ocular Hypertension	-	-
Netarsudil/Latanoprost 0.02%/0.005%	Phase 3	Open Angle Glaucoma	-	-
Latanoprost ophthalmic solution 0.005%	Phase 3	Ocular Hypertension	-	-
AR-13324 Ophthalmic Solution 0.01%	Phase 2	Ocular Hypertension	-	-
PG324 Ophthalmic Solution 0.01%	Phase 2	Open Angle Glaucoma	-	-
AR-15512 Ophthalmic Solution	Phase 2	Dry Eye Disease	-	-
0.25% AR-12286 / 0.004% travoprost	Phase 2	Glaucoma	-	-
AR-13324 Ophthalmic Solution 0.04%	Phase 2	Primary Open Angle Glaucoma or Ocular Hypertension	-	-
AR-12286 0.5% ophthalmic solution	Phase 2	Glaucoma	-	-
AR-102 0.003% Ophthalmic Solution	Phase 2	Glaucoma	-	-
AR-12286 Ophthalmic Solution 0.7%	Phase 2	Ocular Hypertension	-	-
Netarsudil Ophthalmic	Phase 2	Corneal Edema	-	-
Netarsudil Ophthalmic Solution 0.01%	Phase 2	Open Angle Glaucoma	-	-
AR-12286	Phase 2	Elevated Intraocular Pressure	-	-
Latanoprost 0.005%	Phase 2	Glaucoma	-	-
PG286 Ophthalmic Solution 0.5%	Phase 2	Open Angle Glaucoma	-	-
AR-1105-CF1	Phase 2	Macular Edema	-	-

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Market-Implied Move

Regulatory Approvals

Frequently asked questions

What is in Aerie Pharmaceuticals's drug pipeline?→

CatalystAlert tracks 24 drug candidates in Aerie Pharmaceuticals's (AERI) pipeline across Phase 3, Phase 2. Its lead program is Netarsudil ophthalmic solution 0.02% (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Aerie Pharmaceuticals's next FDA catalyst?→

CatalystAlert tracks every upcoming catalyst for Aerie Pharmaceuticals (AERI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.

How do I track AERI biotech catalysts?→

Add AERI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aerie Pharmaceuticals's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Aerie Pharmaceuticals

Market Overview

AERI News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals

Frequently asked questions